Literature DB >> 8522378

Serum antibodies to the components of diphtheria-tetanus-pertussis vaccine in Polish children related to vaccination status.

E Torbicka1, T Lagergård, B Trollfors.   

Abstract

In Poland vaccination against diphtheria, tetanus and pertussis (DTP) is recommended from 2-3 months of age. Three doses at approximately 6-week intervals are given. A booster dose of DTP is given at 19-24 months and boosters of DT at 6 and 14 years. In this study serum samples were obtained from 166 Polish children aged 2 weeks to 14 years. Vaccination status was verified from the children's Health Books. Antibodies were determined against pertussis toxin, filamentous hemagglutinin (FHA), pertactin, tetanus toxoid and diphtheria toxin. Antibodies of maternal original against all five antigens were detected in almost all sera from infants not yet vaccinated. Antibody levels increased with the number of vaccinations given. Children who had recently received the fourth vaccination had the highest antibody levels. Antibody levels decreased with time after the fourth vaccination for all antibodies except FHA. It was concluded that the Polish whole cell pertussis vaccine stimulates antibodies against pertussis toxin, FHA and pertactin, but that antibodies against FHA probably also are stimulated by cross-reacting antigens. Diphtheria toxin and tetanus toxoid antibodies were above protective levels in all vaccinated children, but the long-term decreases justify the booster dose at 14 years. Twenty-five of 166 children (15%) had a vaccination status which deviated from recommendations demonstrating a need to increase the vaccination rate.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8522378     DOI: 10.1007/bf01781199

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  27 in total

1.  Clinical and immunologic responses to the capsular polysaccharide of Haemophilus influenzae type b alone or conjugated to tetanus toxoid in 18- to 23-month-old children.

Authors:  B A Claesson; B Trollfors; T Lagergard; J Taranger; D Bryla; G Otterman; T Cramton; Y Yang; C B Reimer; J B Robbins
Journal:  J Pediatr       Date:  1988-05       Impact factor: 4.406

2.  Immunization of adults against diphtheria and tetanus.

Authors:  G EDSALL
Journal:  Am J Public Health Nations Health       Date:  1952-04

3.  Antibody response to pertussis toxin in patients with clinical pertussis measured by enzyme-linked immunosorbent assay.

Authors:  G Zackrisson; I Krantz; T Lagergård; P Larsson; R Sekura; N Sigurs; J Taranger; B Trollfors
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-04       Impact factor: 3.267

4.  How common is whooping cough in a nonvaccinating country?

Authors:  J Isacson; B Trollfors; J Taranger; G Zackrisson; T Lagergård
Journal:  Pediatr Infect Dis J       Date:  1993-04       Impact factor: 2.129

5.  [Whooping cough in 1991].

Authors:  A Adonajło
Journal:  Przegl Epidemiol       Date:  1993

6.  Pertussis toxin. Affinity purification of a new ADP-ribosyltransferase.

Authors:  R D Sekura; F Fish; C R Manclark; B Meade; Y L Zhang
Journal:  J Biol Chem       Date:  1983-12-10       Impact factor: 5.157

7.  Cloning, expression, and DNA sequence analysis of genes encoding nontypeable Haemophilus influenzae high-molecular-weight surface-exposed proteins related to filamentous hemagglutinin of Bordetella pertussis.

Authors:  S J Barenkamp; E Leininger
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

8.  Subunit structure of islet-activating protein, pertussis toxin, in conformity with the A-B model.

Authors:  M Tamura; K Nogimori; S Murai; M Yajima; K Ito; T Katada; M Ui; S Ishii
Journal:  Biochemistry       Date:  1982-10-26       Impact factor: 3.162

9.  Detection of antibodies in human serum against the fimbrial haemagglutinin of Bordetella pertussis by enzyme-linked immunosorbent assay.

Authors:  M Granström; A A Lindberg; P Askelöf; B Hederstedt
Journal:  J Med Microbiol       Date:  1982-02       Impact factor: 2.472

10.  Safety, immunogenicity and an open, retrospective study of efficacy of a monocomponent pertussis toxoid vaccine in infants.

Authors:  J Isacson; B Trollfors; J Taranger; I MacDowall; J Johansson; T Lagergård; J B Robbins
Journal:  Pediatr Infect Dis J       Date:  1994-01       Impact factor: 2.129

View more
  1 in total

1.  Serum antibodies to diphtheria-tetanus-pertussis vaccine components in Argentine children.

Authors:  M Pasetti; P Eriksson; F Ferrero; M Manghi
Journal:  Infection       Date:  1997 Nov-Dec       Impact factor: 3.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.